Nichols & Pratt Advisers LLP MA Purchases 9,684 Shares of IQVIA Holdings Inc. $IQV

Nichols & Pratt Advisers LLP MA raised its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 8.6% in the third quarter, HoldingsChannel reports. The institutional investor owned 122,603 shares of the medical research company’s stock after acquiring an additional 9,684 shares during the quarter. IQVIA makes up about 1.5% of Nichols & Pratt Advisers LLP MA’s holdings, making the stock its 23rd largest holding. Nichols & Pratt Advisers LLP MA’s holdings in IQVIA were worth $23,287,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently bought and sold shares of IQV. Brighton Jones LLC grew its holdings in IQVIA by 244.4% during the fourth quarter. Brighton Jones LLC now owns 3,575 shares of the medical research company’s stock worth $703,000 after acquiring an additional 2,537 shares during the period. Empowered Funds LLC lifted its stake in shares of IQVIA by 102.1% in the first quarter. Empowered Funds LLC now owns 9,728 shares of the medical research company’s stock worth $1,715,000 after buying an additional 4,915 shares in the last quarter. Sivia Capital Partners LLC acquired a new position in shares of IQVIA during the 2nd quarter valued at about $514,000. Farther Finance Advisors LLC lifted its holdings in IQVIA by 34.0% in the second quarter. Farther Finance Advisors LLC now owns 398 shares of the medical research company’s stock valued at $63,000 after acquiring an additional 101 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. lifted its position in IQVIA by 5.8% in the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 27,185 shares of the medical research company’s stock valued at $4,284,000 after buying an additional 1,489 shares during the last quarter. Institutional investors and hedge funds own 89.62% of the company’s stock.

IQVIA Stock Up 0.6%

Shares of NYSE IQV opened at $231.50 on Tuesday. The firm’s 50-day moving average is $231.00 and its two-hundred day moving average is $209.37. The company has a market capitalization of $39.42 billion, a PE ratio of 31.76, a price-to-earnings-growth ratio of 2.34 and a beta of 1.36. IQVIA Holdings Inc. has a 12-month low of $134.65 and a 12-month high of $247.04. The company has a debt-to-equity ratio of 2.03, a current ratio of 0.70 and a quick ratio of 0.70.

Analysts Set New Price Targets

Several research analysts have recently commented on IQV shares. Stifel Nicolaus raised their price objective on shares of IQVIA from $234.00 to $254.00 and gave the company a “buy” rating in a research note on Wednesday, October 29th. Truist Financial raised their price objective on IQVIA from $265.00 to $290.00 and gave the stock a “buy” rating in a report on Thursday, January 8th. UBS Group increased their price objective on IQVIA from $250.00 to $280.00 and gave the stock a “buy” rating in a research report on Thursday, January 8th. Weiss Ratings reissued a “hold (c)” rating on shares of IQVIA in a report on Thursday, January 22nd. Finally, HSBC upgraded shares of IQVIA from a “hold” rating to a “buy” rating and raised their price objective for the company from $195.00 to $235.00 in a research report on Thursday, October 9th. Two investment analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $251.06.

IQVIA Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.